[1]李　凯　李志强　赵宇航　徐成仕　熊忠伟　陈劲草.脑胶质瘤病人血清β2微球蛋白含量的变化[J].中国临床神经外科杂志,2019,(03):159-161.[doi:10.13798/j.issn.1009-153X.2019.03.011]
　LI Kai,LI Zhi-qiang,ZHAO Yu-hang,et al.Change of serum level of β2-microglobulin in patients with glioma[J].,2019,(03):159-161.[doi:10.13798/j.issn.1009-153X.2019.03.011]
点击复制

脑胶质瘤病人血清β2微球蛋白含量的变化()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
期数:
2019年03期
页码:
159-161
栏目:
论著
出版日期:
2019-03-20

文章信息/Info

Title:
Change of serum level of β2-microglobulin in patients with glioma
文章编号:
1009-153X（2019）03-0159-03
作者:
李　凯　李志强　赵宇航　徐成仕　熊忠伟　陈劲草
作者单位：430071 武汉，武汉大学中南医院神经外科（李　凯、李志强、赵宇航、徐成仕、熊忠伟、陈劲草）
Author(s):
LI Kai;  LI Zhi-qiang;  ZHAO Yu-hang;  XU Cheng-shi;  XIONG Zhong-wei;  CHEN Jin-cao.
Department of Neurosurgery, Zhongnan Hospital, Wuhan University, Wuhan 430071, China
关键词:
脑胶质瘤; 血清β2微球蛋白; IDH1; MGMT
Keywords:
Gliomas;  β2 microglobulin;  Isocitrate dehydrogenase 1;  06-alkylguanuine DNA alkylransferase
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2019.03.011
文献标志码:
A
摘要:
目的 探讨脑胶质瘤病人血清β2微球蛋白（β2-MG）含量的变化。方法 收集2015~2017年手术切除及病理确诊的胶质瘤标本124例，其中WHO Ⅰ级9例，Ⅱ级28例，Ⅲ级34例，Ⅳ级53例。术前2~3 d采取静脉血，通过胶乳免疫比浊法检测血清β2-MG含量；并使用石蜡包埋的胶质瘤组织分别通过毛细管电泳法检测基因异柠檬酸脱氢酶1（IDH1）突变和PCR荧光探针法检测06-甲基鸟嘌呤DNA甲基转移酶（MGMT）基因甲基化状态。结果 WHO Ⅳ级胶质瘤病人血清β2-MG含量显著高于其他级别（WHO Ⅰ~Ⅲ级）胶质瘤（P<0.05）。IDH1突变型胶质瘤病人血清β2-MG含量显著低于野生型病人（P<0.05）。MGMT甲基化胶质瘤病人血清β2-MG含量与非甲基化病人之间无明显差异（P>0.05）。结论 血清β2-MG含量对于WHO Ⅳ级胶质瘤与其他级别件胶质瘤的鉴别以及IDH1突变与野生型的鉴别中可能具有重要的参考意义。
Abstract:
Objective To investigate the change of the serum level of β2-microglobulin (β2-MG) in the patients with glioma and its clinical meaning. Methods Serum β2-MG level was measured by latex immunoturbidimetry in 124 patients with gliomas including 9 with WHO grae Ⅰ gliomas, 28 WHO grade Ⅱ, 34 WHO grade Ⅲ, 53 WHO grade Ⅳ 2~3 days before the operation. The paraffin-embedded glioma tissues were used to detect the mutation of isocitrate dehydrogenase 1 (IDH1) by capillary electrophoresis and the methylation of 06-alkylguanuine DNA alkylransferase (MGMT) gene promoter by PCR fluorescence probe. The differences of the serum levels of β2-MG between the patients with IDH1 wild-type and IDH1 mutionbype gliomas, the ones with methylated and non-methylated MGMT gliomas, and the ones with different WHO grades gliomas. Results The serum level of β2-MG was significantly higher in the patients with WHO grade Ⅳ gliomas than that in the patients with WHO grade Ⅰ~Ⅲ gliomas (P<0.05). The serum level of β2-MG was significantly lower in the patients with IDH1 mutant goliomas than in the patients with IDH1 wild-type goliomas (P<0.05). There was insigificantly difference in the serum level of β2-MG between the patients with MGMT methylation goliomas and the patients with MGMT demethylation goliomas (P>0.05). Conclusion The serum level of β2-MG may be the great helpful to differentiating WHO grade Ⅳ gliomas from other grade gliomas, as well as diffeeretiating IDH1 mutation glioma from wild-type glioma.

参考文献/References:


[1] Norden AD, Wen PY. Glioma therapy in adults [J]. Neurolo-gist, 2006, 12(6): 279-292.
[2] Sasaki T, Ravindranath MH, Terasaki PI, et al. Gastric can-cer progression may involve a shift in HLA-E profile from an intact heterodimer to β2-microglobulin-free monomer [J]. Int J Cancer, 2013, 134(7): 1558-1570.
[3] Pokrass MJ, Liu MF, Lindorfer MA, et al. Activation of com-plement by monoclonal antibodies that target cell-asso-ciated β2-microglobulin: Implications for cancer immuno-therapy [J]. Mol Immunol, 2013, 56(4): 549-560.
[4] Chen Y, Neelapu S, Feng L, et al. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model[J]. Br J Haematol,2016, 175(2): 290-299.
[5] Feder JN, Penny DM, Irrinki A, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding [J]. Proc Natl Acad Sci USA, 1998, 95(4): 1472-1477.
[6] Nomura T HWC, Zhau HE JS, Mimata H CLW. β2-Micro-globulin-mediated signaling as a target for cancer therapy [J]. Anticancer Agents Med Chem, 2014, 14(3): 343-352.
[7] Shi C, Zhu Y, Su Y, et al. Beta2-microglobulin: emerging as a promising cancer therapeutic target [J]. Drug Discov Today, 2009, 14(2): 25-30.
[8] Yang J, Zhang X, Wang J, et al. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells byrecruiting MHC classⅠto and excluding growth and survivalcytokine receptors from lipid rafts [J]. Blood, 2007, 110(8): 3028-3035.
[9] Nomura T, Huang WC, Seo S, et al. Targeting beta2-micro-globulin mediated signaling as a novel therapeutic approachfor human renal cell carcinoma [J]. J Urol, 2007, 178(1): 292-300.
[10] Freeman MR. Beta2 microglobulin: a surprising therapeutic target for prostate cancer and renal cell carcinoma[J]. J Urol,2007, 178(1): 10-11.
[11] Huang WC, Wu D, Xie Z, et al. Beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis [J]. Cancer Res, 2006, 66(18): 9108-9116.
[12] Balint E, Marshall CF, Sprague SM. Role of interleukin-6 in beta2-microglobulin-Ⅰnduced bone mineral dissolution [J]. Kidney Int, 2000, 57(4): 1599-1607.
[13] Rasmuson TGK, Ljungberg B. Serum beta 2-microglobulin and prognosis of patients with renal cell carcinoma [J]. Acta Oncol, 1996, 35(4): 479-482.
[14] 宋芷珩，张朝东，李　为，等. 神经胶质瘤患者血清和脑脊液中β-G活性与β2-MG含量的同步测定及相关性研究[J]. 中国现代医学杂志，2003，9：44-45，64.
[15] Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary [J]. Acta Neuropathol, 2016, 131(6): 803-820.
[16] Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas [J]. N Engl J Med, 2009, 360(8): 765-773.
[17] Wick WWM, van den Bent MSM, Weiler M vDA, et al. MGMT testing--the challenges for biomarker-based gliomatreatment [J]. Nat Rev Neurol, 2014, 10(7): 372-385.

相似文献/References:

[1]邓小芹　胡心英　邓世强.术前预康复在脑胶质瘤手术病人中的应用[J].中国临床神经外科杂志,2020,(03):152.[doi:10.13798/j.issn.1009-153X.2020.03.008]
　DENG Xiao-qin,HU Xin-ying,DENG Shi-qiang..Application of preoperative prehabilitation to patients with gliomas treated by surgery[J].,2020,(03):152.[doi:10.13798/j.issn.1009-153X.2020.03.008]

备注/Memo

备注/Memo:
通讯作者：李志强，E-mail：lizhiqiang@whu.edu.cn
更新日期/Last Update: 2019-03-25